Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Evaluate the Safety and Efficacy of a 5-HT4 Agonist in Chronic Constipation (ACCORD Trial)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00391820
Recruitment Status : Completed
First Posted : October 24, 2006
Last Update Posted : December 3, 2014
Information provided by (Responsible Party):
Theravance Biopharma

Brief Summary:
Study 0038 compares the safety and effectiveness of an investigational drug, TD-5108 with placebo (a sugar pill) for the treatment of chronic constipation.

Condition or disease Intervention/treatment Phase
Chronic Constipation Drug: TD-5108 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 360 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of TD-5108 for the Treatment of Chronic Constipation
Study Start Date : October 2006
Actual Study Completion Date : May 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Constipation

Primary Outcome Measures :
  1. - Clinical response

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 64 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Meet ROME III Criteria

Exclusion Criteria:

  • Constipation caused by:colonic etiology, pelvic floor dysfunction, metabolic disturbances, neurologic disturbances,concomitant medications affecting bowel function
  • Chronic treatment with anticholinergics, narcotic analgesics
  • Irritable Bowel Syndrome

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00391820

Layout table for location information
United States, Texas
Breco Research
Houston, Texas, United States, 77024
Sponsors and Collaborators
Theravance Biopharma
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Theravance Biopharma Identifier: NCT00391820    
Other Study ID Numbers: 0038
First Posted: October 24, 2006    Key Record Dates
Last Update Posted: December 3, 2014
Last Verified: December 2014
Keywords provided by Theravance Biopharma:
bowel function
Additional relevant MeSH terms:
Layout table for MeSH terms
Signs and Symptoms, Digestive